Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Until January 12, 2024
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Until January 12, 2024
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that its 2023 Annual Meeting of Stockholders ("Annual Meeting"), scheduled for Friday, December 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum. The Annual Meeting has been adjourned to 9:00 AM local time on January 12, 2024 at the Company's offices located at 983 University Avenue, Bldg. B, Los Gatos, CA 95032, to allow additional time for stockholders to vote on the proposals set forth in Aridis's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on November 3, 3023.
加利福尼亚州洛斯加托斯，2023年12月15日（GLOBE NEWSWIRE）——专注于发现和开发用于治疗危及生命的感染的新型抗感染疗法的生物制药公司Aridis Pharmicals, Inc.（场外交易QB：ARDS）今天宣布，定于2023年12月15日星期五举行的2023年年度股东大会（“年会”）已召开并休会，但没有结束由于缺乏必要的法定人数而正在开展的任何业务。年会已延期至当地时间2024年1月12日上午9点，地点位于加利福尼亚州洛斯加托斯大学大道983号B栋的公司办公室，目的是让股东有更多时间对Aridis于3023年11月3日向美国证券交易委员会提交的附表14A最终委托书中提出的提案进行投票。
The record date for the Annual Meeting remains November 2, 2023. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action. Company stockholders as of the November 2, 2023 record date can vote, even if they have subsequently sold their shares. The Company's board of directors and management respectfully request all such holders as of the record date to please vote your proxies as soon as possible.
年会的记录日期仍然是2023年11月2日。先前已提交代理书或以其他方式投票但不想更改投票的股东无需采取任何行动。截至2023年11月2日的公司股东可以投票，即使他们随后出售了股票。公司董事会和管理层恭敬地要求截至记录日期的所有此类持有人尽快对您的代理人进行投票。
No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting. The Company strongly advises all of its stockholders to read the proxy statement and other proxy materials relating to the Annual Meeting because they contain important information. Such proxy materials are available at no charge on the Securities and Exchange Commission's website at www.sec.gov. In addition, copies of the Proxy Statement and other documents may be obtained free of charge by accessing or by contacting the Company's Corporate Secretary at 408-385-1742 or by mail to Corporate Secretary, Aridis Pharmaceuticals, Inc., 983 University Avenue, Bldg. B, Los Gatos, CA 95032.
将由股东在年会上表决的提案没有做出任何修改。公司强烈建议其所有股东阅读委托书和其他与年会有关的代理材料，因为它们包含重要信息。此类代理材料可在美国证券交易委员会的网站上免费获得，网址为www.sec.gov。此外，委托书和其他文件的副本可以通过访问或联系公司秘书（电话408-385-1742）或邮寄给位于加利福尼亚州洛斯加托斯大学大道983号B座95032的Aridis Pharmicals, Inc.公司秘书免费获得。
About Aridis Pharmaceuticals, Inc.
关于 Aridis 制药有限公司
Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as first-line treatments to combat antimicrobial resistance (AMR) and viral pandemics. The Company is utilizing its proprietary ʎPEX TM and MabIgX technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture mAbs for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized by the natural human immune system for high potency. Hence, they are already fit-for-purpose and do not require further engineering optimization to achieve full functionality.
Aridis Pharmicals, Inc. 发现并开发抗感染药物，用作对抗抗微生物药物耐药性（AMR）和病毒流行的一线疗法。该公司正在利用其专有的Pex TM和MabiGX技术平台，从成功克服感染的患者身上快速鉴定出稀有、有效的产生抗体的B细胞，并快速制造用于治疗危重感染的单克隆抗体。这些单克隆抗体已经来自人类，并经过天然人类免疫系统的功能优化，具有很高的效力。因此，它们已经适合用途，不需要进一步的工程优化即可实现全部功能。
The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antibacterial and antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care, which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The Company's pipeline is highlighted below:
除了临床前阶段的抗菌和抗病毒单克隆抗体外，该公司还开发了多种针对导致危及生命的感染的细菌的临床阶段单克隆抗体，例如呼吸机相关性肺炎（VAP）和医院获得性肺炎（HAP）。使用单克隆抗体作为抗感染治疗是一种创新的治疗方法，它利用人体免疫系统对抗感染，旨在克服与当前护理标准（即广谱抗生素）相关的缺陷。这些缺陷包括但不限于耐药性增加、疗效持续时间短、人体微生物组正常菌群受到破坏以及当前治疗方法之间缺乏区别。单克隆抗体产品组合辅以一种非抗生素新机制小分子抗感染候选药物，用于治疗囊性纤维化患者的肺部感染。该公司的产品线如下所示：
Aridis' Pipeline
阿里迪斯的管道
AR-301 (VAP). AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive S. aureus alpha-toxin in VAP patients.
AR-301（VAP）。AR-301 是一种全人类 IgG1 单克隆抗体，目前正处于 VAP 患者的革兰氏阳性金黄色葡萄球菌 α-毒素的 3 期临床开发中。
AR-501 (cystic fibrosis). AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients. This program is currently in a Phase 2a clinical study in CF patients.
AR-501（囊性纤维化）。AR-501 是一种吸入式柠檬酸镓配方，具有广谱抗感染活性，用于治疗囊性纤维化患者的慢性肺部感染。该项目目前正在对CF患者进行2a期临床研究。
AR-320 (VAP). AR-320 is a fully human mAb targeting S. aureus alpha-toxin for prevention of VAP. Statistically significant Phase 2 data in the target population of those ≤ 65 years of age was published in the September 2021 Lancet Infectious Diseases journal.
AR-320 (VAP)。AR-320 是一种针对金黄色葡萄球菌 α-毒素的全人单克隆抗体，用于预防 VAP。2021 年 9 月的《柳叶刀传染病》杂志发布了年龄小于 65 岁目标人群的具有统计学意义的 2 期数据。
AR-701 (COVID-19). AR-701 is a cocktail of fully human mAbs discovered from convalescent COVID-19 patients that target multiple sites on the spike proteins of the SARS-CoV-2 virus.
AR-701 (COVID-19)。AR-701 是从恢复期 COVID-19 患者身上发现的全人单克隆抗体的混合物，靶向 SARS-CoV-2 病毒刺突蛋白上的多个位点。
AR-101 (HAP). AR-101 is a fully human IgM mAb in Phase 2 clinical development targeting Pseudomonas aeruginosa liposaccharides serotype O11, which accounts for approximately 22% of all P. aeruginosa hospital acquired pneumonia cases worldwide. This program is licensed to the Serum Institute of India and Shenzhen Arimab.
AR-101（哈哈）。AR-101 是一种全人类 IgM 单抗体，正处于 O11 型铜绿假单胞菌脂质糖血清型，约占全球铜绿假单胞菌医院获得性肺炎病例总数的 22%。该项目已获得印度血清研究所和深圳Arimab的许可。
AR-201 (RSV infection). AR-201 is a fully human IgG1 mAb directed against the F-protein of diverse clinical isolates of respiratory syncytial virus (RSV). This program is licensed exclusively to the Serum Institute of India.
AR-201（呼吸道合胞病毒感染）。AR-201 是一种全人类 IgG1 单抗体，针对呼吸道合胞病毒 (RSV) 多种临床分离株的 F 蛋白。该项目仅获得印度血清研究所的许可。
AR-401 (blood stream infections). AR-401 is a fully human mAb preclinical program aimed at treating infections caused by gram-negative Acinetobacter baumannii.
AR-401（血液感染）。AR-401 是一项全人单克隆抗临床前项目，旨在治疗革兰氏阴性鲍曼不动杆菌引起的感染。